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tion sites in the C terminus of NaV1.5 that impair FGF13-dependent regulation of channel inactivation and may contribute to CaMKII␦c-dependent arrhythmogenic disorders in
failing hearts.

Voltage-gated Na⫹ (NaV) channels are critical determinants
of myocardial excitability, and defects in NaV channel functioning or regulation in the context of inherited or acquired cardiac
disease increase the risk of life-threatening arrhythmias (1).
Under physiological conditions, the primary ventricular NaV
channel subunits, the NaV1.5 channels, activate and inactivate
rapidly to generate the transient peak Na⫹ current, INa, responsible for the depolarization phase and the propagation of action
potentials. However, a small proportion of NaV channels inactivates slowly to generate a late or persistent Na⫹ current,
referred to as INaL, contributing markedly to determining
action potential waveform, duration, and refractoriness. Among
the various determinants recognized to cause NaV channel dysfunctions and consequent increased risk of acquired arrhythmias is the activation of Ca2⫹/calmodulin-dependent protein
kinase II (CaMKII)3 (2–7). A prime example of this dysregulation is heart failure in which an increased INaL has been linked
to the activation of CaMKII (2, 4 –7) and associated alteration
in NaV1.5 phosphorylation (7). This increased INaL in failing
hearts is sometimes accompanied by a decreased NaV channel
availability caused by a hyperpolarizing shift of the voltage
dependence of steady-state INa inactivation (2, 7). Three phosphorylation sites in the first linker loop of NaV1.5, at positions
516 (8, 9), 571 (10 –12), and 594 (8), have been suggested to play
causative roles in these deleterious CaMKII-dependent
mechanisms. Nonetheless, the global native phosphorylation
pattern of NaV1.5 channels associated with CaMKII activation
3

The abbreviations used are: CaMKII, Ca2⫹/calmodulin-dependent protein
kinase II; CaMKII␦c-Tg, transgenic mouse overexpressing the cytosolic isoform of the ␦ subunit of Ca2⫹/calmodulin-dependent protein kinase II;
CTD, C-terminal domain of NaV channels; iFGF, intracellular fibroblast
growth factor; IP, immunoprecipitation; MS1, mass spectrum of precursor
ions; m␣NaVPAN, anti-NaV ␣ subunit monoclonal antibody; NaV ␣ subunit,
voltage-gated Na⫹ (NaV) channel pore-forming (␣) subunit; TTX, tetrodotoxin; FA, formic acid; ACN, acetonitrile; ANOVA, analysis of variance; pF,
picofarad; HP, holding potential; CaM, calmodulin; m, mouse.

J. Biol. Chem. (2017) 292(42) 17431–17448
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

17431

Downloaded from http://www.jbc.org/ at Washington University on January 17, 2018

Voltage-gated Naⴙ (NaV) channels are key regulators of myocardial excitability, and Ca2ⴙ/calmodulin-dependent protein
kinase II (CaMKII)-dependent alterations in NaV1.5 channel
inactivation are emerging as a critical determinant of arrhythmias in heart failure. However, the global native phosphorylation pattern of NaV1.5 subunits associated with these arrhythmogenic disorders and the associated channel regulatory defects
remain unknown. Here, we undertook phosphoproteomic analyses to identify and quantify in situ the phosphorylation sites
in the NaV1.5 proteins purified from adult WT and failing
CaMKII␦c-overexpressing (CaMKII␦c-Tg) mouse ventricles. Of
19 native NaV1.5 phosphorylation sites identified, two Cterminal phosphoserines at positions 1938 and 1989 showed
increased phosphorylation in the CaMKII␦c-Tg compared with
the WT ventricles. We then tested the hypothesis that phosphorylation at these two sites impairs fibroblast growth factor 13
(FGF13)-dependent regulation of NaV1.5 channel inactivation.
Whole-cell voltage-clamp analyses in HEK293 cells demonstrated that FGF13 increases NaV1.5 channel availability and
decreases late Naⴙ current, two effects that were abrogated
with NaV1.5 mutants mimicking phosphorylation at both sites.
Additional co-immunoprecipitation experiments revealed that
FGF13 potentiates the binding of calmodulin to NaV1.5 and that
phosphomimetic mutations at both sites decrease the interaction of FGF13 and, consequently, of calmodulin with NaV1.5.
Together, we have identified two novel native phosphoryla-
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in failing hearts as well as the molecular mechanisms associated
with altered phosphorylation that underlie the defects in channel inactivation remain unknown.
The understanding of NaV1.5 channel inactivation has
received much attention over the past decade and has recently
been buttressed by the generation of several crystal structures
of the cytoplasmic C-terminal domain (CTD) of NaV1.5 (as well
as of other NaV subunits) in complex with Ca2⫹-free or Ca2⫹bound calmodulin (CaM) and/or a member of the intracellular
fibroblast growth factor (iFGF) family of proteins (13–16). The
Ca2⫹-binding protein CaM acts as a sensor for Ca2⫹ and regulates inactivation of NaV channels, while underlying mechanisms still elude consensus. Depending on whether CaM is
loaded with Ca2⫹, it binds different sites within and around the
IQ motif in the CTD and/or the third linker loop of NaV channels, thereby inducing conformational changes and affecting
channel inactivation and the late Na⫹ current (13–19). iFGFs,
which include FGF11–14, are also constitutive NaV channelassociated proteins, binding the CTD of NaV channels, just
upstream of the IQ motif (14 –16, 20 –22). The most consistent
effect of iFGFs is to increase the availability of NaV channels by
shifting the voltage dependence of steady-state inactivation
toward depolarized potentials (15, 20 –26). The central role of
the NaV1.5 CTD as well as of iFGFs and CaM in regulating the
inactivation properties of NaV1.5 channels is highlighted by the
effects of several mutations observed in the arrhythmic long
QT3 (LQT3) and Brugada syndromes that map to their binding
interfaces (14, 27–29).
This study uses a mass spectrometry (MS)-based phosphoproteomic analysis to identify and quantify in situ the native
phosphorylation sites in the NaV1.5 proteins purified from failing CaMKII␦c-overexpressing (CaMKII␦c-Tg) versus non-failing wild-type (WT) mouse ventricles. The rationale for using
this transgenic and failing mouse model is to identify the
NaV1.5 phosphorylation sites that participate in the channel
inactivation defects associated with the activation of CaMKII␦c
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in heart failure. Further biochemical and electrophysiological
approaches in human embryonic kidney 293 (HEK293) cells
were then used to investigate the impact of phosphorylation at
two C-terminal serine residues on the interaction of FGF13 and
CaM with NaV1.5 and on the inactivation properties of NaV1.5
channels.

Results
Purification and characterization of NaV channel complexes
from WT and CaMKII␦c-Tg mouse ventricles
Total lysates from four adult WT and four CaMKII␦c-Tg (30)
mouse (m) ventricles were prepared, pooled, and used in eight
distinct IPs (four WT IPs and four CaMKII␦c-Tg IPs) using the
m␣NaVPAN-specific antibody. As illustrated in Fig. 1A and
consistent with previous findings (7), Western blot analyses of
total lysates showed greater NaV1.5 protein expression in the
CaMKII␦c-Tg compared with the WT ventricles. This difference in total protein expression resulted in significantly (p ⬍
0.05) higher NaV1.5 protein abundance (3.8-fold) in the
m␣NaVPAN-IPs from the CaMKII␦c-Tg than from the WT
ventricles (Fig. 1, A and B). Accordingly, analyses of m␣NaVPANIPs on SYPRO Ruby-stained gels revealed the presence of a
band corresponding to the molecular weight of NaV ␣ subunits
(31), the intensities of which are higher in the CaMKII␦c-Tg IPs
than in the WT IPs (Fig. 1C).
The protein components of isolated NaV channel complexes
from WT and CaMKII␦c-Tg ventricles were identified by MS
using three distinct mass spectrometers: an LTQ-Orbitrap XL,
an LTQ-Orbitrap Elite, and a TripleTOF 5600 Plus. The NaV1.5
protein was the most abundant protein in the m␣NaVPAN-IPs
from both WT and CaMKII␦c-Tg ventricles with average numbers of total exclusive MS/MS spectra acquired increasing from
95 using the Orbitrap XL to 177 using the Orbitrap Elite and
524 using the TripleTOF (Fig. 2A). These greater sensitivities of
the Orbitrap Elite and TripleTOF mass spectrometers improved
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Figure 1. Immunoprecipitation of NaV channel complexes from adult WT and CaMKII␦c-Tg mouse ventricles. A, representative NaV ␣ Western blots
of total lysates and immunoprecipitated proteins from adult WT and CaMKII␦c-Tg mouse ventricles with the anti-NaVPAN monoclonal antibody (m␣NaVPANIPs) probed with the anti-NaV1.5 rabbit polyclonal (Rb␣NaV1.5) and the m␣NaVPAN antibodies, respectively. B, mean ⫾ S.E. relative NaV ␣ protein abundance
in WT (n ⫽ 4) and CaMKII␦c-Tg (n ⫽ 4) IPs. *, p ⬍ 0.05, Mann-Whitney test. C, SYPRO Ruby-stained gel of m␣NaVPAN-IPs from WT and CaMKII␦c-Tg mouse
ventricles. Relative abundance of proteins running at the molecular weight of NaV ␣ subunits is higher in CaMKII␦c-Tg IPs than in WT IPs.
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Figure 2. MS protein identification in immunoprecipitated NaV channel complexes from WT and CaMKII␦c-Tg mouse ventricles. A, NaV ␣ subunits
identified using the LTQ-Orbitrap XL, LTQ-Orbitrap Elite, and TripleTOF 5600 Plus mass spectrometers. The average numbers of exclusive unique peptides and
total spectra for each NaV ␣ subunit and the percent amino acid sequence coverages obtained for NaV1.5, including or excluding transmembrane domains (TD),
are presented. In addition to NaV1.5, which is the most abundant protein in the m␣NaVPAN-IPs, NaV1.4 is also detected, and the greater sensitivity of the
Orbitrap Elite and TripleTOF mass spectrometers allowed the identification of NaV1.7, NaV1.8, and NaV1.3. B, amino acid sequence coverage obtained for the
(mouse) NaV1.5 protein (NP_001240789). Detected peptides are highlighted in yellow; identified phosphorylation sites are highlighted in blue (sites already
identified in our previous MS analyses) and red (newly identified sites in the present study); transmembrane segments (S1–S6) in each domain (I–IV) are in bold
and underlined in black; loops I, II, and III correspond to interdomains I and II, II and III, and III and IV, respectively; and binding sites for iFGF and calmodulin
(IQ-motif) are boxed in green and orange, respectively. C, relative abundances of NaV ␣ subunits and previously characterized NaV1.5 channel-associated/
regulatory proteins in the CaMKII␦c-Tg IPs (n ⫽ 4) versus the WT IPs (n ⫽ 4) were calculated from the entire (Orbitrap XL) MS1 peptide data set using the DAnTE
statistical software (**, p ⬍ 0.01; ***, p ⬍ 0.001).
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the NaV1.5 amino acid sequence coverage from 27 to 28 and
32%, respectively, and from 36 to 38 and 43% with the transmembrane domains removed. NaV1.4 was the second most
abundant NaV ␣ subunit with much fewer spectra acquired: 5,
7, and 30 using the Orbitrap XL, Orbitrap Elite, and TripleTOF,
respectively. Most interestingly, the greater sensitivity of the
TripleTOF mass spectrometer allowed the identification of
three additional NaV ␣ subunits, NaV1.7 (four spectra), NaV1.3
(three spectra), and NaV1.8 (two spectra). These experiments
also led to the reliable identification of several previously identified NaV1.5 channel-associated/regulatory proteins (32),
including the ␦, ␤, and ␥ subunits of CaMKII, CaM, FGF13, and
ankyrin-G (Fig. 2C). The supplemental Tables 1–3 provide the
complete lists of identified peptides and proteins using the
Orbitrap XL, Elite, and the TripleTOF mass spectrometers,
respectively.
The relative abundances of identified proteins in the m␣NaV
PAN-IPs from the CaMKII␦c-Tg versus the WT ventricles were
calculated from the MS1 peptide data (Orbitrap XL) using the
DAnTE statistical analysis tool (33–35). Consistent with the
biochemistry data (Fig. 1), the NaV1.5 protein is 2.9-fold (p ⬍
0.001) more represented in the CaMKII␦c-Tg IPs than in the
WT IPs (Fig. 2C). Interestingly, this quantitative MS analysis
also revealed that of the 10 NaV1.5-associated/regulatory proteins identified, the abundance ratios of CaMKII␦, ␤2-syntrophin, and dystrophin in the CaMKII␦c-Tg versus the WT IPs
are substantially greater than the 2.9-fold abundance ratio
obtained for NaV1.5. On the contrary, the CaMKII␤ and ␥ subunits as well as CaM and FGF13 are relatively less represented
compared with NaV1.5. The abundance ratios obtained for
ankyrin-G, plakophilin-2, and ␣1-syntrophin are close to the
NaV1.5 abundance ratio. Taken together, these observations
demonstrate that NaV1.5 is more expressed in the CaMKII␦cTg than in the WT mouse ventricles, which, as a consequence,
led to greater NaV1.5 IP yields from the CaMKII␦c-Tg than
from the WT ventricles. These analyses also suggest different
relative compositions of associated/regulatory proteins in
NaV1.5 channel complexes in the CaMKII␦c-Tg compared with
the WT ventricles.
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Identification of native NaV1.5 phosphorylation sites from WT
and CaMKII␦c-Tg mouse ventricles
To determine the global native phosphorylation pattern
of NaV1.5 channels associated with the overexpression of
CaMKII␦c, a quantitative phosphoproteomic analysis of the
NaV1.5 proteins purified from the CaMKII␦c-Tg and the WT
mouse ventricles was performed. This phosphoproteomic analysis unambiguously allowed the identification of 19 native phosphorylation sites in the mouse ventricular NaV1.5 protein (Figs.
2B and 3). Table 1 lists the phosphopeptides enabling the best
phosphorylation site assignment(s), with the mass spectrometer used for the identification and the percentages of maximum
intensities of site-discriminating ions, for each phosphorylation
site. Representative MS/MS (and MS1) phosphopeptide spectra are presented in supplemental Fig. 1. Descriptions of all
detected site-discriminating and supporting ions (calculated
mass errors, confirmations of charge states) are given in supplemental Tables 4. Among the 19 NaV1.5 phosphoserines
(pSer) or phosphothreonines (pThr) identified, 10 (in blue) had
already been identified in our previous phosphoproteomic
analyses (31) and nine (in red) are novel (Figs. 2B and 3). These
nine novel phosphorylation sites are located in the first (pThr486, pSer-499, pSer-516, and pSer-539) and second (pSer-1012)
intracellular linker loops as well as in the CTD (pSer-1888,
pSer-1937, pSer-1938, and pSer-1989) of NaV1.5. Interestingly,
the three C-terminal pSer-1888, pSer-1937, and pSer-1938 are
in close proximity to the binding sites for the iFGFs (14 –16,
20 –22) and CaM (IQ-motif) (13–19).
To determine whether one or several of these MS-identified
NaV1.5 phosphorylation sites are associated with the overexpression of CaMKII␦c, the relative abundance of each NaV1.5
phosphopeptide in the CaMKII␦c-Tg versus the WT m␣NaVPANIPs was determined by label-free quantification of MS1 data
(36). As illustrated in Fig. 4A, and consistent with the quantification of the biochemical (Fig. 1) and the MS protein (Fig. 2C)
data, the unphosphorylated NaV1.5 peptides are 3.6-fold more
represented in the CaMKII␦c-Tg versus the WT IPs. Of the 86
unphosphorylated and 32 phosphorylated NaV1.5 peptides

Downloaded from http://www.jbc.org/ at Washington University on January 17, 2018

Figure 3. Localization of MS-identified in situ phosphorylation sites on the mouse ventricular NaV1.5 ␣ subunit protein. Among the 19 phosphorylation
sites identified, 10 (in blue) had already been identified in our previous MS analyses and 9 (in red) are novel. Four and two phosphorylation site locations are
possible at amino acids 36 – 42 and 524 –525, respectively. The three newly identified C-terminal phosphoserines at positions 1888, 1937, and 1938 (pSer-1888,
pSer-1937, and pSer-1938) are in close proximity to the binding sites for iFGF and calmodulin (IQ-motif).

Phosphorylation and inactivation of cardiac NaV1.5 channels
Table 1
Phosphorylation sites, phosphopeptides, and site-discriminating ions identified in immunoprecipitated NaV1.5 ␣ subunits from adult WT
and/or CaMKII␦c-Tg mouse ventricles using MS
The site-discriminating ions observed in the high-resolution (LTQ-Orbitrap Elite or TripleTOF 5600 Plus) or low-resolution (LTQ-Orbitrap XL) MS/MS spectra of each
annotated NaV1.5 phosphopeptide support the assignment of the indicated phosphorylation site(s). The charge state as well as the percentage of maximum intensity of each
observed unphosphorylated and phosphorylated site-discriminating (b and y) ion are reported in parentheses; the minus symbol indicates that the charge state could not
be determined.
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(118 peptides total), only the three phosphopeptides AT(pS)
DNLPVR, RL(pS)(pS)GTEDGGDDR, and AL(pS)AVSVLTSALEELEESHRK (marked with a † in Fig. 4A), exhibiting
phosphorylation(s) on serines 1989 (pSer-1989), 483 and 484
(pSer-483 and pSer-484), and 664 (pSer-664), respectively,
present fold change ratios (8.96-, 7.13-, and 0.58-fold) significantly different from the median ratio (Tukey whisker analysis,
Fig. 4B). Nonetheless, the other phosphopeptides assigning
pSer-483 and/or pSer-484 do not show any significant abundance changes compared with the median ratio (Fig. 4, A and
B); and the abundance change observed for the phosphopeptide
identifying pSer-664 is not significantly different between the
m␣NaVPAN-IPs from the CaMKII␦c-Tg and the WT ventricles
(Fig. 4A). In addition, the phosphopeptide Q(⫺17.03)QAGSS-

GLSDEDAPER, assigning pSer-1937 and/or pSer-1938 (Table
1), is present in the CaMKII␦c-Tg IPs (n ⫽ 3/4) and absent in
the WT IPs (n ⫽ 0/4) (Fig. 4C). Relative abundances of all
the other NaV1.5 phosphopeptides are comparable with the
median (or mean) relative abundance found for the unphosphorylated NaV1.5 peptides (Fig. 4, A and B).
Amino acid sequence alignment of the flanking regions of
pSer-1937/38 and pSer-1989 showed a good conservation of
Ser-1938 and Ser-1989 across orthologous sequences (Ser-1937
is not well-conserved) and, interestingly, revealed that Ser-1989
conforms to the consensus CaMKII phosphorylation site
(RXX(S/T) Fig. 4D (37)). Taken together, these phosphoproteomic analyses identified nine novel native NaV1.5 phosphorylation sites, of which two conserved serines in the CTD, at
J. Biol. Chem. (2017) 292(42) 17431–17448
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positions 1938 and 1989, show increased phosphorylation in
the CaMKII␦c-Tg compared with the WT ventricles.
Phosphorylation at serines 1933 and 1984 impairs FGF13dependent regulation of NaV1.5 channel inactivation
To determine the impact of phosphorylation at these two
C-terminal (mouse) serines 1938 and 1989 on the gating properties of NaV1.5 channels, the orthologous human serine to
glutamate (NaV1.5-S1933E/S1984E, NaV1.5-EE) or serine to
alanine (NaV1.5-S1933A/S1984A, NaV1.5-AA) double NaV1.5
phosphomutants were generated and analyzed by whole-cell
voltage-clamp analyses in transiently transfected HEK293 cells.
Because pSer-1938 and pSer-1989 are located in close proximity to the binding site for the iFGFs (14 –16, 20 –22), we tested
the hypothesis that phosphorylation at these two sites disrupts
the interaction of the iFGFs with NaV1.5 and the associated

17436 J. Biol. Chem. (2017) 292(42) 17431–17448

iFGFs-dependent regulation of NaV1.5 channel function. To
this purpose, initial experiments were aimed at exploring the
effects of FGF13 on the current density and biophysical properties of heterologously expressed NaV1.5 channels. The isoform 2 of FGF13 (FGF13–2) was chosen as the iFGF in these
experiments as it is the isoform detected in the m␣NaVPANIPs. As illustrated in Fig. 5, these whole-cell voltage-clamp analyses demonstrated that FGF13 significantly decreases the peak
Na⫹ current (INa) density (p ⬍ 0.05, Fig. 5, A and B) and shifts
the voltage dependence of steady-state current inactivation
toward depolarized potentials (p ⬍ 0.01, Fig. 5D, see detailed
densities, properties, and statistics in Table 2). In contrast, no
significant differences in the voltage dependence of activation
(Fig. 5C) or the kinetics of activation, inactivation, and recovery
from inactivation were observed upon FGF13 co-expression
(Table 2). To determine the effect of NaV1.5 phosphorylation at
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Figure 4. Quantification analysis of NaV1.5 phosphorylation sites in the CaMKII␦c-Tg versus the WT m␣NaVPAN-IPs. A, relative abundances of 32 NaV1.5
phosphopeptides allowing assignments of the listed phosphorylation sites, in the CaMKII␦c-Tg (n ⫽ 4) versus the WT (n ⫽ 4) IPs, were calculated using label-free
quantification of the (Orbitrap XL) MS1 data. The mean ⫾ S.E. relative abundance of unphosphorylated NaV1.5 peptides in the CaMKII␦c-Tg versus the WT IPs
was calculated from 86 unphosphorylated NaV1.5 peptides (minimum Scaffold peptide probability scores of 95%). Consistent with the biochemistry data (Fig.
1) and the DAnTE protein statistical analysis (Fig. 2C), the unphosphorylated NaV1.5 peptides are 3.6-fold more represented in the CaMKII␦c-Tg IPs than in the
WT IPs (red dashed line). The relative abundances of individual NaV1.5 phosphopeptides are significantly (*, p ⬍ 0.05, Mann-Whitney test) different in the
CaMKII␦c-Tg compared with the WT IPs. B, Tukey whisker analysis of NaV1.5 peptide relative abundance in CaMKII␦c-Tg versus WT IPs. Of the 118 (86 unphosphorylated and 32 phosphorylated) NaV1.5 peptides, only the phosphopeptides AT(pS)DNLPVR, RL(pS)(pS)GTEDGGDDR, and AL(pS)AVSVLTSALEELEESHRK
(marked with † in A), exhibiting phosphorylation(s) on serines 1989 (pSer-1989), 483 and 484 (pSer-483 and pSer-484), and 664 (pSer-664), respectively, present
fold change ratios (8.96-, 7.13-, and 0.58-fold) significantly different from the median ratio. C, mean ⫾ S.E. intensities of phosphopeptides
Q(⫺17.03)QAGSSGLSDEDAPER, assigning pSer-1937 and/or pSer-1938 (absence in WT IPs and presence in CaMKII␦c-Tg IPs), and AT(pS)DNLPVR, assigning
pSer-1989 (8.96-fold change ratio), in WT (n ⫽ 4) and CaMKII␦c-Tg (n ⫽ 4) IPs. *, p ⬍ 0.05, Mann-Whitney test. D, conservation of the two C-terminal NaV1.5
serines 1938 and 1989 across orthologs.

Phosphorylation and inactivation of cardiac NaV1.5 channels
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Figure 5. Phosphorylation at serines 1933 and 1984 disrupts the FGF13-dependent increase in steady-state NaV1.5 channel availability. A, representative whole-cell voltage-gated Na⫹ currents recorded from transiently transfected HEK293 cells. Currents were obtained 48 h following transfection of
HEK293 cells with NaV1.5-WT (black), NaV1.5-WT ⫹ FGF13 (green), NaV1.5-S1933E/S1984E ⫹ FGF13 (NaV1.5-EE ⫹ FGF13, red), NaV1.5-S1933A/S1984A ⫹ FGF13
(NaV1.5-AA ⫹ FGF13, blue), NaV1.5-S1933E/S1984E (NaV1.5-EE, purple), and NaV1.5-S1933A/S1984A (NaV1.5-AA, pink) using the protocols illustrated in each
panel. B, mean ⫾ S.E. peak Na⫹ current (INa) densities are plotted as a function of test potential. C, voltage dependence of current activation. Mean ⫾ S.E.
normalized conductances (GNa) are plotted as a function of test potential and fitted using a Boltzmann equation. D, voltage dependence of steady-state current
inactivation. Mean ⫾ S.E. normalized current amplitudes are plotted as a function of prepulse potential and fitted using a Boltzmann equation. FGF13
significantly (p ⬍ 0.01 versus NaV1.5-WT, one-way ANOVA followed by the Dunnett’s post hoc test) shifts the voltage dependence of NaV1.5 channel inactivation toward depolarized potentials, an effect reversed with the NaV1.5-EE phosphomutant (p ⬍ 0.01 versus NaV1.5-WT ⫹ FGF13, one-way ANOVA followed by
the Dunnett’s post hoc test). E, no significant changes in voltage dependence of steady-state current inactivation were observed between NaV1.5-WT,
NaV1.5-EE, and NaV1.5-AA in the absence of FGF13. Detailed densities, properties, and statistics are provided in Table 2.

serines 1933 and 1984 on these FGF13-dependent regulations,
these analyses were repeated from cells co-expressing NaV1.5-EE
or NaV1.5-AA and FGF13. These recordings revealed that the
voltage dependence of steady-state inactivation in cells co-expressing NaV1.5-EE and FGF13 is significantly (p ⬍ 0.01)
shifted toward hyperpolarized potentials compared with cells
co-expressing NaV1.5-WT and FGF13 and similar to cells

expressing NaV1.5-WT alone (Fig. 5D and Table 2). In contrast,
the NaV1.5-AA phosphomutant co-expressed with FGF13
showed voltage dependence of inactivation properties similar
to those recorded from cells co-expressing NaV1.5-WT and
FGF13. No changes in peak INa density, voltage dependence of
activation, or kinetics of activation, inactivation, and recovery
from inactivation were observed with either the NaV1.5-EE or
J. Biol. Chem. (2017) 292(42) 17431–17448
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Table 2
Voltage-gated Naⴙ current densities and properties in transiently transfected HEK293 cells
The peak Na⫹ current density (INa), time to peak, and time course of inactivation properties presented were determined from analyses of records obtained on depolarizations to ⫺20 mV (HP ⫽ ⫺120 mV). All values are means ⫾ S.E. The number of cells analyzed is provided in parentheses. *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001 versus
NaV1.5-WT; ##, p ⬍ 0.01 versus NaV1.5-WT ⫹ FGF13; one-way ANOVA followed by the Dunnett’s post-hoc test.
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FGF13 on channel inactivation properties, which results in
decreased channel availability and increased INaL.
Phosphorylation at serines 1933 and 1984 decreases the
interaction of FGF13 and CaM with NaV1.5
To explore the hypothesis that phosphorylation at serines
1933 and 1984 in NaV1.5 impairs the regulation of channel
inactivation mediated by FGF13 by altering the binding of
FGF13 and/or CaM to the channel, co-immunoprecipitation
experiments were completed using the same experimental paradigm as above. As illustrated in Fig. 7A, FGF13 and (endogenous) CaM co-immunoprecipitate with NaV1.5, whether in the
WT, NaV1.5-AA, or NaV1.5-EE forms, in HEK293 cells. Interestingly, however, the relative abundances of FGF13 (Fig. 7B)
and CaM (Fig. 7C) are significantly (p ⬍ 0.01 and p ⬍ 0.001,
respectively) lower in the NaV1.5 immunoprecipitates from
cells expressing the NaV1.5-EE phosphomutant compared with
cells expressing the WT channels. No changes were observed
with the NaV1.5-AA phosphomutant. Parallel negative controls
of co-immunoprecipitations obtained from cells transiently
transfected with FGF13 or NaV1.5-WT alone confirmed the
specificity of detected signals. To determine whether phosphorylation at only one site was sufficient to decrease the interaction
of FGF13 or CaM with the channel, co-immunoprecipitations
were performed with the single alanine or glutamate phosphomutant channels. Consistent with the electrophysiological findings,
no significant changes in binding affinity were observed with any
of the single phosphomutant channels (Fig. 7, B and C).
Additional co-immunoprecipitation experiments were then
designed to determine whether FGF13 and CaM influence each
other for the binding to the channel. Interestingly, these experiments revealed that co-expression of FGF13 significantly (p ⬍
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NaV1.5-AA phosphomutants compared with the NaV1.5-WT
co-expressed with FGF13 (Fig. 5, A–C, and Table 2). In addition, no changes in the voltage dependences of inactivation
were observed between NaV1.5-WT (V1⁄2 ⫽ ⫺84.5 ⫾ 0.6 mV,
n ⫽ 24), NaV1.5-EE (V1⁄2 ⫽ ⫺83.9 ⫾ 0.5 mV, n ⫽ 18), and
NaV1.5-AA (V1⁄2 ⫽ ⫺84.1 ⫾ 0.7 mV, n ⫽ 13) in the absence of
FGF13 (Fig. 5E), suggesting that FGF13 plays a pivotal role
in mediating this phosphorylation-dependent effect. Finally,
mimicking or abolishing phosphorylation at only one of the two
phosphorylation sites (in cells co-expressing NaV1.5-S1933E,
NaV1.5-S1933A, NaV1.5-S1984E, or NaV1.5-S1984A with
FGF13) did not show any significant changes on peak INa density or channel biophysical properties compared with cells coexpressing NaV1.5-WT and FGF13 (Table 2).
Additional voltage-clamp experiments were designed to
examine the effects of FGF13 and of NaV1.5 phosphomutants
on the late Na⫹ current. These analyses showed that the TTXsensitive late Na⫹ current (INaL) density is significantly (p ⬍
0.001) smaller in cells co-expressing NaV1.5 and FGF13 than in
cells expressing NaV1.5 alone (Fig. 6, A and B, and Table 3).
Interestingly, this effect was significantly (p ⬍ 0.05) abrogated
in cells co-expressing NaV1.5-EE and FGF13 (Fig. 6, A and B,
and Table 3). However, no such abrogation of the FGF13 effect
was observed with the NaV1.5-AA phosphomutant (Fig. 6, C
and D, and Table 3). In addition, similar to the biophysical
properties, no significant effects on INaL could be detected in
the absence of FGF13 (INaL ⫽ ⫺0.32 ⫾ 0.04 pA/pF, n ⫽ 27 for
NaV1.5-WT; INaL ⫽ ⫺0.46 ⫾ 0.07 pA/pF, n ⫽ 28 for NaV1.5-EE;
and INaL ⫽ ⫺0.25 ⫾ 0.05 pA/pF, n ⫽ 15 for NaV1.5-AA, see Fig.
6E) or with the simple phosphomutants (Table 3). Taken
together, these results suggest that simultaneous phosphorylation at serines 1933 and 1984 on NaV1.5 impairs the effects of

Phosphorylation and inactivation of cardiac NaV1.5 channels
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Figure 6. Phosphorylation at serines 1933 and 1984 disrupts the FGF13-dependent decrease in INaL. TTX-sensitive late Na⫹ current (INaL) recordings were
obtained 48 h after transfection of HEK293 cells in three different data sets. The first data set (A and B) was obtained from cells expressing NaV1.5-WT (black),
NaV1.5-WT ⫹ FGF13 (green), and NaV1.5-S1933E/1984E ⫹ FGF13 (NaV1.5-EE ⫹ FGF13, red); the second data set (C and D) from cells expressing NaV1.5-WT
(black), NaV1.5-WT ⫹ FGF13 (green), and NaV1.5-S1933A/S1984A ⫹ FGF13 (NaV1.5-AA ⫹ FGF13, blue); and the third data set (E) from cells expressing NaV1.5-WT
(black), NaV1.5-S1933E/S1984E (NaV1.5-EE, purple), and NaV1.5-S1933A/S1984A (NaV1.5-AA, pink). A and C, representative TTX-sensitive INaL recordings evoked
by prolonged depolarizations (350 ms at ⫺20 mV) from a holding potential of ⫺120 mV. The scale bars indicate a current amplitude of 10 pA, which
corresponds to a current density of 0.8 pA/pF and time (50 ms). B, D, and E, distributions and mean ⫾ S.E. TTX-sensitive late Na⫹ current (INaL) densities. *, p ⬍
0.05; ***, p ⬍ 0.001 versus NaV1.5-WT; #, p ⬍ 0.05 versus NaV1.5-WT ⫹ FGF13; ns, non-significant; Kruskal-Wallis one-way ANOVA followed by the Dunn’s post
hoc test. Detailed densities and statistics are provided in Table 3.

0.01) increases the binding of CaM to NaV1.5 (Fig. 7, D and E).
Conversely, overexpression of CaM did not influence the binding of FGF13 to the channel (Fig. 7, D and E). Additionally, no
changes in the binding of CaM to NaV1.5-EE or NaV1.5-AA,
compared with NaV1.5-WT, were observed in the absence of

FGF13 (Fig. 7F). Together, these biochemical analyses suggest
that FGF13 potentiates the binding of CaM to NaV1.5 and that
phosphorylation at both serines 1933 and 1984 decreases
the interaction of FGF13 and, consequently, of CaM with the
channel.
J. Biol. Chem. (2017) 292(42) 17431–17448
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Table 3
Late Naⴙ current densities in transiently transfected HEK293 cells
The TTX-sensitive late Na⫹ current (INaL) densities were measured at ⫺20 mV (HP ⫽ ⫺120 mV). All values are means ⫾ S.E. The number of cells analyzed is provided in
parentheses. *, p ⬍ 0.05; ***, p ⬍ 0.001 versus NaV1.5-WT; #, p ⬍ 0.05 versus NaV1.5-WT ⫹ FGF13; Kruskal-Wallis one-way ANOVA followed by the Dunn’s post-hoc test.

CaMKII␦c-dependent phosphorylation map of native mouse
NaV1.5 channels
The present phosphoproteomic analysis confidently identified a total of 19 native phosphorylation sites in the NaV1.5
channel proteins purified from mouse ventricles, of which nine
are novel. Consistent with our previous MS analysis (31), and
with another phosphoproteomic analysis of human NaV1.5
channels purified from HEK293 cells (9), the great majority (13
of 19) of identified phosphorylation sites are located in the first
intracellular linker loop of the channel, suggesting critical roles
for this region in mediating phosphorylation-dependent regulation of cardiac NaV1.5 channels. However, none of these 13
phosphorylation sites identified in the first linker loop, including phosphoserine 571 which was reported to be CaMKII␦c-dependent (11, 12), appeared to be regulated in the CaMKII␦c-Tg
ventricles compared with the WT ventricles. Note that no relative quantification could be obtained for the low abundance
phosphopeptides assigning phosphoserines 516 and 1888, and
that the region surrounding threonine 594 was not covered
(Fig. 2B), precluding possible detection and quantification of
phosphothreonine 594. The only two/three phosphorylation
sites showing significant and consistent abundance changes in
the CaMKII␦c-Tg compared with the WT ventricles are located
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in the CTD of NaV1.5, at position(s) 1937 and/or 1938 and at
position 1989. Although localization(s) of phosphorylation
could not be discriminated between serines 1937 and 1938
in the singly phosphorylated peptide allowing quantification
(presence in the CaMKII␦c-Tg IPs, and absence in the WT IPs),
we focused our attention on serine 1938 (human serine 1933)
because serine 1937 is not well-conserved across species and is
notably absent in human. In addition, the human NaV1.5 phosphoserine 1933 has previously been shown to be CaMKII␦c-dependent in in vitro phosphoproteomic analyses (9), underscoring the potential involvement of CaMKII␦c in phosphorylating
this site. Finally, it is also important to note here that the relative
quantification of the doubly phosphorylated peptide supporting phosphorylation at both serines 1937 and 1938 (Table 1)
could not be obtained because of low abundance, yet this peptide was only detected in the CaMKII␦c-Tg IPs. The number of
phosphorylation sites identified here in association with the
overexpression of CaMKII␦c in mouse ventricles (two phosphoserines) could seem little compared with the results of the
previous phosphoproteomic study of human NaV1.5 channels
in which 23 phosphorylation sites, of the 34 identified, were
found to be phosphorylated in vitro by CaMKII␦c. These seemingly distinct findings might reflect the fact that different experimental approaches were employed. Indeed, although phosphorylation sites were identified from native, in situ phosphorylated NaV1.5 channels in this study, previous MS analysis was
performed from heterologously-expressed NaV1.5 channels
that were immunoaffinity-purified and subsequently subjected
to in vitro phosphorylation by recombinant CaMKII␦c. It is also
stressed here that although the present MS analysis was performed from ventricles in which CaMKII␦c is overexpressed,
we cannot exclude the involvement of other kinases/phosphatases whose activity may also be changed. Consistent with the
direct implication of CaMKII␦c, however, the in vitro phosphoproteomic analyses of human NaV1.5 demonstrated that
human phosphoserine 1933 is CaMKII␦c-dependent (9). Likewise, it is interesting to note that mouse phosphoserine 1989
(and human phosphoserine 1984) is located in a well-conserved
consensus CaMKII phosphorylation site (37). Together, these
MS analyses from mouse ventricles therefore suggest that the
two NaV1.5 phosphoserines at positions 1938 and 1989 are
associated with the overexpression of CaMKII␦c.
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Discussion
The results presented here provide two novel phosphorylation maps of native mouse NaV1.5 channel subunits purified
from control WT and failing CaMKII␦c-overexpressing ventricles, and they delineate two novel C-terminal phosphoserines,
at positions 1938 and 1989, that are up-regulated in the failing
CaMKII␦c-overexpressing ventricles. Mechanistic analyses in
HEK293 cells revealed that mimicking phosphorylation at both
sites (in the human sequence) impairs the regulation of NaV1.5
channels by FGF13, resulting in decreased channel availability
and increased late Na⫹ current. Co-immunoprecipitation
experiments demonstrated that FGF13 potentiates the binding
of CaM to NaV1.5 and that FGF13 and, consequently, CaM
bindings are decreased when phosphorylation at both sites is
mimicked. Overall, these results provide evidence for a novel
phosphorylation-dependent mechanism that acts at the level of
the NaV1.5 channel macromolecular complex through regulation of specific protein/protein interactions.

Phosphorylation and inactivation of cardiac NaV1.5 channels
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Figure 7. Phosphorylation at serines 1933 and 1984 decreases the interaction of FGF13 and consequently of CaM with NaV1.5. Forty eight hours
following transfection of HEK293 cells with NaV1.5-WT, NaV1.5-S1933A/S1984A (NaV1.5-AA), NaV1.5-S1933E/S1984E (NaV1.5-EE), NaV1.5-S1933A (1933A),
NaV1.5-S1933E (1933E), NaV1.5-S1984A (1984A), NaV1.5-S1984E (1984E), FGF13, and/or CaM, cell lysates were prepared and used for IPs with the m␣NaVPAN
antibody. A, D, and F, representative Western blots of the lysates (left panel) and the immunoprecipitates (right panel) with the monoclonal anti-NaVPAN,
anti-FGF13, and/or anti-CaM antibodies. Relative mean ⫾ S.E. FGF13 (B) and CaM (C) abundances in m␣NaVPAN-IPs from cells expressing NaV1.5-WT (WT, n ⫽
8), NaV1.5-AA (AA, n ⫽ 8), and NaV1.5-EE (EE, n ⫽ 8); NaV1.5-WT (WT, n ⫽ 5 and 4, respectively), 1933A (n ⫽ 6 and 4, respectively), and 1933E (n ⫽ 6 and 4,
respectively); and NaV1.5-WT (WT, n ⫽ 6), 1984A (n ⫽ 6), and 1984E (n ⫽ 6). E, relative mean ⫾ S.E. CaM abundances in m␣NaVPAN-IPs from cells expressing
NaV1.5-WT (n ⫽ 8) and NaV1.5-WT ⫹ FGF13 (n ⫽ 12), and FGF13 abundances in m␣NaVPAN-IPs from cells expressing NaV1.5-WT ⫹ FGF13 (n ⫽ 4) and NaV
1.5-WT ⫹ FGF13 ⫹ CaM (n ⫽ 4). **, p ⬍ 0.01; ***, p ⬍ 0.001 versus NaV1.5-WT, Kruskal-Wallis one-way ANOVA followed by the Dunn’s post hoc test (B and C), or
Mann-Whitney test (E). FGF13 and CaM abundances in each IP were first normalized to immunoprecipitated NaV1.5 and then expressed relative to FGF13 or
CaM abundances in IPs from control conditions.

FGF13-dependent regulation of NaV1.5 channel inactivation
Because our MS findings converged on the possible involvement of NaV1.5 C-terminal phosphorylation sites in mediating
CaMKII␦c-dependent channel regulation and that the CTD of
NaV channels is well-recognized for its role in regulating channel inactivation through the binding of iFGFs (15, 20 –26) and

CaM (13–19), we first characterized the roles of FGF13 in regulating NaV1.5 channels in HEK293 cells. Our findings are in
accordance with previous data demonstrating a key role for
FGF13 in increasing steady-state NaV1.5 channel availability,
although the amplitude of the presently observed effect (⬃2
mV) is smaller than previously reported effects of FGF13 or
J. Biol. Chem. (2017) 292(42) 17431–17448
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Impairment of FGF13-dependent NaV1.5 channel inactivation
by phosphorylation
Determination of the impact of phosphorylation at serines
1933 and 1984 in the regulation of NaV1.5 channels first
revealed that the binding of FGF13 and CaM to NaV1.5 is
reduced with the double-glutamate phosphomutant compared
with the WT channels, suggesting that phosphorylation at
these serines disables the interaction of FGF13 and CaM with
the channel. Most importantly, this reduced interaction, as
assessed by co-immunoprecipitation, correlates with an impairment of functional modulation. Indeed, all the effects of
FGF13 on NaV1.5-generated currents, but those on the peak
density were nearly completely abolished with the double-glutamate phosphomutant, therefore resulting in decreased channel availability and increased late Na⫹ current. Together, these
analyses show that mimicking phosphorylation at serines 1933
and 1984, which according to these and previous findings (9)
are not phosphorylated at baseline in HEK293 cells, impairs
FGF13-dependent regulation of NaV1.5 channel inactivation.
Of note, these functional effects associated with the decreased
FGF13 and CaM bindings are similar to those previously
observed with several NaV1.5 mutants in which the binding of
CaM to the NaV1.5 CTD is disrupted (17, 19, 29). Mimicking
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phosphorylation at only one site, however, did not lead to any
consistent alterations in the interaction of FGF13 or CaM with
the channel nor in the functional regulation by FGF13, suggesting that phosphorylation at both sites is necessary to disable
FGF13/CaM bindings and associated dysregulation of channel
inactivation. Consistent with these findings in HEK293 cells,
our MS analyses also revealed different relative compositions of
associated/regulatory proteins in NaV1.5 channel complexes in
the CaMKII␦c-Tg ventricles compared with the WT ventricles.
Of particular interest, indeed, the FGF13 and CaM relative
abundances in the CaMKII␦c-Tg IPs compared with the WT IP,
are lower (2-fold abundance ratios) than the 3-fold abundance
ratios obtained for NaV1.5 or ankyrin-G. Together, therefore,
these analyses suggest that phosphorylation at serines 1933 and
1984 impairs the binding of FGF13 and CaM to NaV1.5 and abrogates FGF13-dependent regulation of channel inactivation.
FGF13 potentiates the binding of CaM to NaV1.5, and
phosphorylation-dependent disruption of FGF13 binding
to NaV1.5 results in reduced CaM binding
To further delineate the relationship between FGF13 and
CaM for the binding to NaV1.5 and subsequent phosphorylation-dependent regulation, the same electrophysiological and
biochemical analyses were performed in the absence of FGF13.
Interestingly, neither the channel availability nor the late Na⫹
current or the CaM/NaV1.5 interaction were altered in the
absence of FGF13, highlighting the primary role of FGF13
in this phosphorylation-dependent regulation. These findings
also suggest that the decreased CaM binding to the doubleglutamate phosphomutant channel is subsequent to the decreased FGF13 binding. In this respect, further co-immunoprecipitation experiments were performed to examine the
relationship between FGF13 and CaM for the binding to
NaV1.5. Remarkably, these analyses revealed that FGF13 substantially increases the binding of CaM to the channel, demonstrating for the first time that the binding of CaM to NaV1.5 is
potentiated by the binding of FGF13. Inversely, no changes in
FGF13 binding were observed upon CaM overexpression, suggesting that CaM does not influence the binding of FGF13.
Whether phosphorylation or FGF13 influence directly the
Ca2⫹/CaM dependence of NaV1.5 channel inactivation
remains to be investigated. Interestingly, these novel findings
are evocative of recent observations from the Pitt group (29)
demonstrating that the increased late Na⫹ current associated
with several LQT3 syndrome mutations within the NaV1.5
CTD correlates with a decreased binding of apoCaM to the
NaV1.5 CTD. In line with these findings, the recently reported
LQT3-causing mutation at p.H1849R in the NaV1.5 CTD is also
associated with an impairment of iFGF binding and iFGF-mediated regulation of NaV1.5 channels (28). Together with these
two previous studies, our results herein support the overall
hypothesis that the binding of FGF13 and/or CaM to the
NaV1.5 CTD is pivotal in the regulation of channel inactivation,
as unveiled by C-terminal phosphorylation and disease mutations within the NaV1.5 CTD, and that impairment of iFGF
and/or CaM modulation may constitute a common mechanism
to inherited (CTD-mutated LQT3 patients) and acquired
(CaMKII␦c-associated) arrhythmias.
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other iFGFs (⬃5–10 mV) (15, 20 –26). Interestingly, our data
also provide a novel role for FGF13 in decreasing the late Na⫹
current in HEK293 cells. The role of FGF13, and in particular of
FGF13-2, in regulating the late Na⫹ current had only been
investigated once in tsA201 cells, and it was shown to have no
effect (26). These different findings perhaps are due to differences in the heterologous expression systems used or are due to
the fact that no NaV␤ subunits were included in the previous
study compared with this study in which NaV1.5 channels were
co-expressed with FGF13–2 and NaV␤1. Consistent with this
negative effect of FGF13 on the late Na⫹ current, the conditional knock-out of FGF13 in murine hearts revealed longer
action potential durations (25), which could well be caused by
an increased late Na⫹ current. The answer to this question
must await further analysis of the late Na⫹ current from this or
other FGF13 animal models. The observed decrease in peak
Na⫹ current density upon FGF13 co-expression was somewhat
surprising in light of previous findings in native cardiomyocytes
demonstrating a decreased NaV1.5 channel cell-surface expression upon FGF13 knockdown (21) or a reduced peak Na⫹ current density in ventricular myocytes isolated from FGF13
conditional knock-out mice (25). This lack of consistency is
nonetheless reminiscent of previous investigations of iFGF-dependent regulation of NaV channels from Pitt and co-workers,
who reported the same disparate effects on peak Na⫹ current
density in native (increase) (21, 25) and heterologous (decrease)
(26) cells, and it may reflect differences in channel cellular and
molecular environment. In addition, note that no differences in
peak Na⫹ current densities were observed in ventricular
myocytes isolated from FGF13 knock-out and WT mice (24).
In summary, these results suggest that FGF13 primarily regulates the inactivation properties of NaV1.5 channels from
both the closed state (increased availability) and the open
state (decreased late Na⫹ current).

Phosphorylation and inactivation of cardiac NaV1.5 channels
Potential broader implication of phosphorylation-dependent
regulation of NaV1.5 channels in heart failure

Experimental procedures
Animals were handled in accordance with the guidelines
from Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientific purposes. Experimental protocols were approved by the local animal care and use
committee (Comité d’Ethique pour l’Expérimentation Animale
des Pays de la Loire, authorization CEAA.2010.9). Generation
and characterization of the CaMKII␦c-Tg mouse line have been
described previously (30). Cardiac tissues for in vitro experiments were harvested after euthanasia of the mice by cervical
dislocation.
Immunoprecipitations of NaV channel complexes
Flash-frozen ventricles from four 13-month-old CaMKII␦cTg and four age- and sex-matched WT mice were homogenized
as described previously (31) in ice-cold lysis buffer containing
20 mM HEPES (pH 7.4), 150 mM NaCl, 0.5% amidosulfobetaine
(Sigma), 1⫻ complete protease inhibitor mixture tablet (Roche
Applied Science), 1 mM phenylmethylsulfonyl fluoride (PMSF,
Interchim), 0.7 g/ml pepstatin A (Thermo Fisher Scientific),
and 1⫻ Halt phosphatase inhibitor mixture (Thermo Fisher
Scientific). After a 15-min rotation at 4 °C, 8 mg of the pooled
WT or CaMKII␦c-Tg ventricular soluble protein fractions were
pre-cleared with 200 l of protein G-magnetic beads (Pierce)
for 1 h and subsequently used for IPs with 48 g of an antiNaVPAN mouse monoclonal antibody (m␣NaVPAN, Sigma,
S8809), raised against the SP19 epitope (39) located in the third
intracellular linker loop and common to all NaV ␣ subunits.
Prior to the IP, antibodies were cross-linked to 200 l of pro-

Gel electrophoreses and Western blot analyses
Ten percent of the immunoprecipitated mouse ventricular
NaV channel protein complexes were fractionated on onedimensional polyacrylamide gels and analyzed using either
SYPRO Ruby (Life Technologies, Inc.) staining or Western
blotting using the m␣NaVPAN antibody (1:2000, Sigma, S8809)
as described previously (31). The total ventricular lysates were
blotted with a rabbit polyclonal anti-NaV1.5 antibody (1:2000,
Rb␣NaV1.5, Alomone, ASC-005). Western blot analyses of protein eluates from co-immunoprecipitations of heterologously
expressed proteins were performed using the following primary antibodies: mouse monoclonal anti-NaVPAN (1:2000,
m␣NaVPAN, Sigma, S8809); mouse monoclonal anti-FGF13
(1:300, clone N91/27, NeuroMab Facility, University of California Davis, NINDS/NIMH, National Institutes of Health); and
rabbit monoclonal anti-CaM (1:300, Abcam, EP799Y). Bound
antibodies were detected using horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibodies
(Santa Cruz Biotechnology), and protein signals were visualized
using the SuperSignal West Dura Extended Duration Substrate
(Pierce). The intensities of co-immunoprecipitated FGF13 or
CaM bands were normalized to the intensities of immunoprecipitated NaV1.5 bands from the same IP sample, and FGF13 or
CaM abundances in immunoprecipitations from experimental
conditions are expressed relative to abundances in immunoprecipitations from control conditions.
In-solution endoprotease digestions
Samples for mass spectrometry were prepared as described
previously (31). Briefly, eluted proteins were precipitated using
the 2D protein clean-up kit (GE Healthcare). The resulting pellets were dissolved in 8 M urea, 100 mM Tris (pH 8.5), reduced
with 5 mM tris(2-carboxyethyl)phosphine (pH 8.0) for 30 min at
room temperature, and alkylated with 10 mM iodoacetamide
(Bio-Rad) for 30 min at room temperature. Samples were then
digested with 1 g of endoproteinase Lys-C (Roche Applied
Science) overnight at 37 °C and subsequently with 4 g of trypsin (Sigma) overnight at 37 °C. Peptides were acidified with formic acid to a final concentration of 1%, extracted with NuTip
porous graphite carbon wedge tips (Glygen), and eluted with
aqueous acetonitrile (ACN, 60%) containing formic acid (FA,
0.1%). The extracted peptides were dried, dissolved in aqueous
J. Biol. Chem. (2017) 292(42) 17431–17448
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Evidence suggests that some of the arrhythmogenic abnormalities associated with heart failure are triggered by the activation of CaMKII (2, 30) and a subsequent CaMKII-dependent
increase in INaL (4 –7). By identifying two novel NaV1.5 phosphorylation sites up-regulated in CaMKII␦c-Tg ventricles,
which are failing (30), and by demonstrating roles for these sites
in altering NaV1.5 channel inactivation, our results provide evidence for a model in which increased CaMKII␦c-dependent
NaV1.5 phosphorylation at serines 1933 and 1984 may provide
an arrhythmic substrate in heart failure. Nonetheless, it is
unclear whether the functional consequences of impaired
FGF13 and CaM binding to NaV1.5 by phosphorylation, as
observed here in HEK293 cells, fully match up with the NaV
channel defects associated with heart failure. Indeed, although
the increased late Na⫹ current is a consistent finding in failing
cardiomyocytes from both human and animal models (2, 4 –7,
38), evidence for a decreased NaV channel availability has only
been observed, to our knowledge, in the CaMKII␦c-Tg mice (7)
and in a failing dog model induced by left-bundle branch ablation and right atrial pacing (2). Besides, the activation of CaMKII has consistently been associated with an increased INaL and
a decreased NaV1.5 channel availability (3, 7, 8, 11, 12). Overall,
the molecular mechanisms elucidated here may be relevant in
conditions of increased CaMKII␦c expression and/or activity
and may partly contribute to the arrhythmias associated with
heart failure.

tein G-magnetic beads using 20 mM dimethyl pimelimidate
(Thermo Fisher Scientific) (40). Protein samples and antibodycoupled beads were mixed for 2 h at 4 °C. Magnetic beads were
then collected and washed rapidly four times with ice-cold lysis
buffer, and isolated protein complexes were eluted from the
beads in 2% Rapigest (41) (Waters), 8 M urea (Sigma), 100 mM
Tris (pH 8.5) at 37 °C for 30 min.
For co-immunoprecipitations of heterologously expressed
proteins, HEK293 cells were washed twice with PBS and lysed
in lysis buffer (as above) 48 h after transfection. Soluble protein fractions were collected and incubated with 12.5 l of
m␣NaVPAN-coupled magnetic beads (as above). After a 2-h
incubation at 4 °C, beads were washed four times in lysis buffer,
and protein complexes were eluted with 1⫻ SDS sample buffer
at 60 °C for 5 min.
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ACN/FA (1%/1%), stored at ⫺80 °C, and subsequently analyzed
using one-dimensional liquid chromatography-tandem mass
spectrometric experiments (LC-MS/MS).
Mass spectrometric analyses
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MS data processing and analyses
The LC-MS raw files from the LTQ-Orbitrap XL and Elite
were processed using MASCOT Distiller (version 2.3.02,
Matrix Science) with settings previously described (31). The
TripleTOF data were processed using the SCIEX MS Data Converter (version 1.3, SCIEX), converting the raw data files (*.wiff)
to mgf files. The resulting MS2 centroid files were used for
database searching with MASCOT (version 2.3.02) against the
UNIPROT mouse protein database (downloaded on May 2,
2011, with 72,510 entries for the XL data, and on December 20,
2011, with 77,200 entries for the Elite and the TripleTOF data)
using the following parameters: trypsin as the enzyme, MS tolerances of 50 (XL), 10 (Elite), and 25 (TripleTOF) ppm; MS/MS
tolerances of 0.8 (XL), 0.05 (Elite), and 0.1 (TripleTOF) Da, with
a fixed carbamidomethylation of Cys residues and variable
modifications being oxidation (Met), pyro-glutamination
(Gln), and phosphorylation (Ser, Thr, and/or Tyr), a maximal
number of missed cleavages of 4, and ⫹1, ⫹2, ⫹3, and ⫹4
charge states. Scaffold (versions 3.1.4.1 (XL), 4.4.3 (Elite) and
3.6.4 (TripleTOF), Proteome software) was used to validate
MS2-based peptide and protein identifications with the Peptide
(44) and Protein (45) Prophet algorithms using thresholds of 50
and 95%, respectively. The supplemental Tables 1–3 provide
the complete lists of identified peptides and proteins using the
LTQ-Orbitrap XL, Elite, and the TripleTOF mass spectrometers, respectively.
Phosphopeptide spectra were manually interpreted by comparing the observed mass values from the spectrum in XCalibur
(LTQ-Orbitrap XL and Elite data) or PeakView (TripleTOF
data) with the theoretical parent and fragment NaV1.5 ion mass
values from MS-Product. Annotations of MS2 spectra were
first automated using java-based software, which matches observed m/z values with theoretical fragment masses from
MS-Product, and definitive annotations were subsequently
obtained by manual verification and interpretation. Mass accuracy tolerances of 20 ppm or 0.5 Da were used as guidelines for
high- and low-resolution spectral annotations, respectively,
and only those ions with mass errors within these ranges were
included to determine residue coverage and location of phosphorylation site(s). Additionally, for spectral annotation of
high-resolution MS2 data, charge states of observed parent and
fragment ions were determined, and only precursor, b- and
y-ions with confirmed charge states (i.e. with at least the presence of the 13C isotope peak) were used. The phosphorylation
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Peptide mixtures were analyzed using nano-LC-MS on three
high-resolution hybrid mass spectrometers, a linear quadrupole ion trap Orbitrap XL (LTQ-Orbitrap XL) (31), an LTQOrbitrap Elite (42) (both from Thermo Fisher Scientific), and a
TripleTOF威 5600 Plus (SCIEX) (43). The chromatograph was a
2D Plus (Eksigent) LC with a Nanoflex module and AS2
autosampler in dual cHiPLC columns (ChromXP C18 200
m ⫻ 15 cm; particle size 3 m, 120 Å) configuration. The
mobile phases were 1% FA in water (A) and 1% FA in ACN (B).
The liquid chromatographs were interfaced to the mass spectrometers through a nanospray source (PicoView PV550, New
Objective). The samples were loaded in a volume of 5–10 l at
a flow rate of 1.5 l/min followed by organic gradient elution of
peptides (800 nl/min). The LC conditions for analyses on the
LTQ-Orbitrap XL and LTQ-Orbitrap Elite were performed
after equilibrating the columns in 98% solvent A and 2% solvent
B followed by 2% B, 0 –5 min; 2- 25% B, 5–110 min; 25– 80% B,
110 –170 min; 80 –2% B, 170 –175 min; and isocratic elution at
2% B, 175–190 min. The survey scans (m/z 350 –2000) (MS1)
were acquired at high resolution (60,000 at m/z 400) in the
Orbitrap XL, and the MS2 spectra were acquired in the linear
ion trap at low resolution, both in profile mode. The maximum
injection times for the MS1 scans in the Orbitrap and the LTQ
were 500 and 200 ms, respectively. The automatic gain control
targets for the Orbitrap and the LTQ were 5 ⫻ 105 and 3 ⫻ 104,
respectively, with maximum injection times of 100 ms for the
MS2 scans. The MS1 scans were followed by three MS2 events
in the linear ion trap with collision activation in the ion trap
(parent threshold 1000, isolation width 2.0 Da, normalized collision energy 30%, activation Q 0.250, and activation time 30
ms). Dynamic exclusion was enabled (⫺0.20/⫹1.0 Da) for 90 s
after MS2 acquisitions. A repeat count of 1, a repeat duration of
45 s, and a maximal exclusion list size of 500 were used. The
following ion source parameters were used: capillary temperature 200 °C, source voltage 3.0 kV, source current 100 A, capillary voltage 33 V, and tube lens 120 V. Data were acquired
using XCalibur, version 2.2 SP1 (Thermo Fisher Scientific). For
data acquisition on the LTQ-Orbitrap Elite, the following modifications were employed. The survey scans (m/z ⫽ 300 –1650)
were acquired at a resolution of 120,000 with a target value of
1e6 ions. The HCD MS2 acquisitions were performed for the
top 15 most intense ions at a resolution of 15,000, a target value
of 40,000 and a low mass setting of 120 m/z. For collision-induced dissociation, a collision energy of 40% was used with an
activation time of 100 ms. Dynamic exclusion was enabled (30
s) without MS2 acquisition of ⫹1 charged parent ions. The data
were acquired using Xcalibur, version 2.0.7 (Thermo Fisher
Scientific).
The LC-MS analysis on the TripleTOF威 5600 Plus mass
spectrometer was obtained using the following gradient elution
program: 0 time, 98% A, 2% B; 5 min, 2% A, 98% B; 415 min, 65%
A, 35% B; and 440 min, 20% A, 80% B. Initial chromatographic
conditions were restored in 5 min and maintained for 20 min.

The ion spray voltage was set at 2.9 kV, the curtain gas at
10 p.s.i., the nebulizer gas at 14 p.s.i., and the interface heater
temperature set at 175 °C. The MS1 data were acquired at a
resolution of 25,000 with a scan range of 400 –1200 m/z in 250
ms. The top 50 product ions were selected for MS2 acquisition
with a dwell time of 100 ms. Four time bins were summed for
each scan at a frequency of 15.4 kHz (through monitoring of the
40 GHz multichannel TDC detector with four-anode/channel
detection). A rolling collision energy (CE) was applied to all
precursor ions for collision-induced dissociation using the following equation: CE ⫽ slope䡠m/z ⫹ intercept, where the slope
for all charge states above ⫹2 is 0.0625 and the intercept is ⫺3,
⫺5, and ⫺6 for ⫹2, ⫹3, and ⫹4, respectively.
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Plasmids
The simple and double NaV1.5 phosphomutant constructs
were generated by mutating the serines 1933 and/or 1984 to
alanine(s) or glutamate(s) by site-directed mutagenesis of the
pCI-NaV1.5 plasmid containing the human NaV1.5 hH1C
cDNA (46) (NCBI Reference Sequence NM_000335) using the
QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) with the following primers (with mutations underlined): NaV1.5-S1933A-F, 5⬘-cagcaggcgggcgccggcctctccga, and
NaV1.5-S1933A-R, 5⬘-tcggagaggccggcgcccgcctgctg; NaV1.5S1933E-F, 5⬘-cgtcagcaggcgggcgaaggcctctccgaagag, and NaV1.5S1933E-R 5⬘-ctcttcggagaggccttcgcccgcctgctgacg; NaV1.5-S1984A-F,
5⬘-tgtcactagagccaccgccgataacctccaggtg, and NaV1.5-S1984A-R
5⬘-cacctggaggttatcggcggtggctctagtgac; NaV1.5-S1984E-F 5⬘agtgtcactagagccaccgaagataacctccaggtgcgg, and NaV1.5-S1984E-R
5⬘-ccgcacctggaggttatcttcggtggctctagtgacact. The mutated constructs were then digested with restriction endonucleases to
excise the mutated fragments, which were then subcloned
into the original pCI-NaV1.5 plasmid. The human NaV␤1
(NM_001037, a gift from A. L. George) and rat CaM
(NM_017326, a gift from I. Deschenes) cDNAs were subcloned

into pRc/CMV and pcDNA3, respectively. The human transcript variant 2 of FGF13 (FGF13–2, NM_001139500), subcloned into pCMV6-XL5, was purchased from Amsbio. All constructs were sequenced to ensure that no unintentional
mutations were introduced.
Culture and transient transfections
HEK293 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Life Technologies, Inc.) supplemented with 10% fetal bovine serum, 100 units/ml penicillin,
and 100 g/ml streptomycin, in 37 °C, 5% CO2, 95% air incubator. Cells were transiently transfected at 70 – 80% confluence in
35-mm dishes with 0.9 g of the WT or phosphomutant NaV1.5
plasmid, 0.45 g of the NaV␤1 plasmid, with or without 0.45 g
of the FGF13 plasmid using 2 l of Lipofectamine 2000 (Life
Technologies, Inc.) following the manufacturer’s instructions. For patch-clamp recordings, transfections also contained 0.2 g of the pEGFP plasmid (enhanced green fluorescent protein plasmid, Clontech), so that the enhanced
GFP expression serves as a marker of transfection. The absolute
amounts of the various constructs were calculated, and the
empty pcDNA3.1 plasmid (Life Technologies, Inc.) was used as
a filler plasmid to keep the total DNA constant at 2 g in each
transfection.
Electrophysiological recordings
Whole-cell NaV currents were recorded at room temperature from transiently transfected HEK293 cells using an Axopatch 200A amplifier (Axon Instruments) 48 h after transfection. Voltage-clamp protocols were applied using the pClamp
10.2 software package (Axon Instruments) interfaced to the
electrophysiological equipment using a Digidata 1440A digitizer (Axon Instruments). Current signals were filtered at 10 kHz
prior to digitization at 50 kHz and storage. Patch-clamp
pipettes were pulled from borosilicate glass (outer diameter is
1.5 mm and inner diameter is 0.86 mm, Sutter Instrument)
using a P-97 micropipette puller (Sutter Instrument), coated
with wax, and fire-polished to a resistance between 1.5 and 2.5
megohms when filled with internal solution. The internal solution contained (in mM): NaCl 5, CsCl 105, HEPES 10, glucose 5,
EGTA 10, CaCl2 8.7 (1 M free [Ca2⫹], calculated with MaxChelator) and Mg-ATP 5 (1 mM free [Mg2⫹], MaxChelator)
(pH 7.2 with CsOH, ⬃300 mosM). The external (low Na⫹) solution contained (in mM): NaCl 25, CsCl 94, tetraethylammonium
chloride 25, HEPES 10, glucose 5, CaCl2 1, MgCl2 2 (pH 7.4 with
CsOH, ⬃300 mosM). All the chemicals were purchased from
Sigma. After establishing the whole-cell configuration, 3 min
were allowed to ensure stabilization of the voltage dependence
of inactivation properties, at which time 25-ms voltage steps to
⫾10 mV from a holding potential (HP) of ⫺70 mV were applied
to allow measurement of whole-cell membrane capacitance,
input, and series resistances. Only cells with access resistance
⬍7 megohms were used, and input resistances were typically
⬎5 giga-ohms. After compensation of series resistance (80%),
the membrane was held at a HP of ⫺120 mV, and the voltageclamp protocols were carried out as indicated below. Leak currents were always ⬍200 pA at the HP (⫺120 mV) and corrected
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site assignments were based on the presence or absence of the
unphosphorylated and phosphorylated b- and y-ions flanking
the site(s) of phosphorylation, ions that we call site-discriminating ions throughout this study. When site-discriminating
ions were not all detected, assignments of phosphorylation sites
were narrowed down to one, two (for pSer-524 and/or pSer525), or four (for pSer-36, pThr-38, pSer-39, and/or pSer-42)
possibility(ies) by elimination. In addition to mass accuracy
and charge state, the relative percentage of maximum intensity of site-discriminating ions or of any supporting ions in
each analyzed spectrum was also considered for spectral
annotation. Representative MS1 and MS2 spectra used for
each of the phosphorylation site assignments, mass errors of
parent ions (in ppm), and Mascot Ion scores for each phosphopeptide are presented in supplemental Fig. 1. The definition of all observed site-discriminating ions, as well as the
calculated mass errors and charge state confirmations for all
supporting b- and y-ions (as well as for, when detected, the
loss of phosphoric acid peaks) are summarized in Table 1
and supplemental Tables 4.
The label-free quantitative MS analysis of protein abundance
in the IPs was performed from the entire (LTQ-Orbitrap XL)
MS1 peptide data set using the DAnTE (Data Analysis Tool
Extension) software (33–35). To perform label-free quantitative analyses of mass spectra of precursor ion (MS1 peptides)
data, the LTQ-Orbitrap XL MS1 and MS2 data from
quadruplicate analyses of m␣NaVPAN-IPs from WT and
CaMKII␦c-Tg mouse ventricles were imported into Rosetta
ElucidatorTM (version 3.3, Rosetta Biosoftware) for retention
time and m/z alignment of the peptide ion chromatograms
using previously described parameters (36). Peak intensities of
MS1 peptide features were quantified, and normalization of
intensities across samples was performed using the average signal intensities obtained in each sample. Ion chromatograms
and isotopic distributions of aligned NaV1.5 peptides were all
visually inspected.
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(Tocris Bioscience). Only cells exhibiting peak current amplitudes of ⬎4000 pA were used (those with peak current of
⬍4000 pA did not show measurable late Na⫹ current), and cells
with difference in leak current amplitudes before and after TTX
application of ⬎2 pA at ⫺20 mV (calculated from leak currents
at ⫺120 mV) were excluded from analyses. TTX-sensitive currents from individual cells were determined by off-line digital
subtraction of average leak-subtracted currents obtained from
five recordings in the absence and in the presence of TTX after
achieving steady state. The amplitude of TTX-sensitive late
Na⫹ current was defined as the steady-state current amplitude
(A0) obtained by fitting the inactivation decay of macroscopic
TTX-sensitive current with the double exponential function
I(t) ⫽ Aslow ⫻ exp(⫺t/slow) ⫹ Afast ⫻ exp(⫺t/fast) ⫹ A0. For
each cell, the TTX-sensitive late Na⫹ current amplitude was
normalized to the Cm, and expressed as TTX-sensitive late
Na⫹ current density (in pA/pF).
Statistical analyses
Results are expressed as means ⫾ S.E. Data were first tested
for normality using the D’Agostino and Pearson normality test.
Depending on the results of normality tests, statistical analyses
were then performed using the Mann-Whitney nonparametric
test, the one-way ANOVA followed by the Dunnett’s post hoc
test, or the Kruskal-Wallis one-way ANOVA followed by the
Dunn’s post hoc test as indicated in the figures and tables. All of
these analyses, the Tukey whisker analysis and the plots, were
performed using Prism (GraphPad software).
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Supplementary Data
Burel et al.
Legend of Supplementary Figures 1. Representative high- or low-resolution tandem mass (MS2)
spectra of singly, doubly or triply phosphorylated NaV1.5 tryptic peptides (listed in Table 1)
demonstrating the phosphorylation of the serines 36, 39, 42 and/or the threonine 38 (pS36, pT38, pS39
and/or pS42), the serines 457 (pS457), 460 (pS460), 483 (pS483), 484 (pS484), 497 (pS497), 499
(pS499), 510 (pS510), 516 (pS516), 524 and/or 525 (pS524 and/or pS525), 539 (pS539), 571 (pS571),
664 (pS664), 1012 (pS1012), 1888 (pS1888), 1937 (pS1937), 1938 (pS1938) and 1989 (pS1989), and
the threonine 486 (pT486). The small insets show representative spectra of precursor ions (MS1
spectra) that were used and fragmented to produce the MS2 spectra. The presence of the y(highlighted in blue) and b- (in red) ion series describing the amino acid sequences, of the loss of
phosphoric acid peaks (in green) as well as of the unphosphorylated and phosphorylated sitediscriminating (or supporting) ions unambiguously supported the assignments of the indicated
phosphorylation site(s). The mass errors of parent ions (in ppm) and the Mascot Ion scores for each
phosphopeptide are indicated at the top of each page. The charge state confirmations and the
percentage of maximum intensities of site-discriminating ions are presented in Table 1, and the
complete list of assigned ions is given in Supplementary Tables 4.
Legend of Supplementary Tables 1, 2 and 3. Lists of identified peptides and proteins using the
LTQ-Orbitrap XL (1), the LTQ-Orbitrap Elite (2) and the TripleTOF 5600 Plus (3) mass
spectrometers. In each peptide data table (spreadsheets #1), the MASCOT ion score, the observed m/z
and the calculated mass error (in ppm) are shown. In the protein tables (spreadsheets #2), the percent
protein identification probability, the exclusive unique peptide and spectrum counts, the exclusive
spectrum count and the percent amino acid sequence coverage are indicated.
Legend of Supplementary Tables 4. The calculated mass errors (in ppm) and charge state
confirmations (presence or absence of the 13C isotopic peak) for all supporting b- and y-ions (as well
as for the loss of phosphoric acid peaks) observed in the high- or low-resolution MS2 spectra of each
annotated NaV1.5 phosphopeptide (listed in Table 1 and represented in Supplementary Figures 1) are
summarized. Spreadsheet titles indicate the m/z values of the presented phosphopeptides.
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Nerbonne_029_2506_291_10_ #7340 (LTQ-Orbitrap Elite, high-resolution MS2)
GSATSQESREGLPEEEAPRPQLDLQASK (aa 35-62), m/z = 773.365, +4, 1P (pS36, pT38, pS39 and/or pS42)
Mass error: -0.29 ppm, Mascot Ion score: 19.3
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Nerbonne_029_2506_263_10_ #8909.2 (TripleTOF 5600, high-resolution MS2)
GVDTV(pS)RS(pS)LEMSPLAPVTNHER (aa 452-474), m/z = 661.305, +4, 2P (pS457 + pS460)
Mass error: 9.8 ppm, Mascot Ion score: 81.9
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Nerbonne_029_2506_291_11_ #8882 (LTQ-Orbitrap Elite, high-resolution MS2)
GVDTVSRS(pS)LEMSPLAPVTNHER (aa 452-474), m/z = 854.739, +3, 1P (pS460)
Mass error: -0.48 ppm, Mascot Ion score: 87.3
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Nerbonne_029_2506_263_11_ #6250.4 (TripleTOF 5600, high-resolution MS2)
RL(pS)(pS)GTEDGGDDRLPK (aa 481-496), m/z = 621.596, +3, 2P (pS483 + pS484)
Mass error: 2.7 ppm, Mascot Ion score: 75.7
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Nerbonne_029_2506_263_11_ #5919.7 (TripleTOF 5600, high-resolution MS2)
KRLSSGTEDGGDDRLPK (aa 480-496), m/z = 664.294, +3, 2P (pS483 or pS484 + pT486)
Mass error: 3.3 ppm, Mascot Ion score: 41.1
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Nerbonne_029_2506_263_10_ #6268.10 (TripleTOF 5600, high-resolution MS2)
RL(pS)(pS)G(pT)EDGGDDRLPK (aa 481-496), m/z = 648.251, +3, 3P (pS483 + pS484 + pT486)
Mass error: 1.5 ppm, Mascot Ion score: 28.5
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Nerbonne_029_2506_263_11_ #5998.6 (TripleTOF 5600, high-resolution MS2)
LS(pS)GTEDGGDDRLPK (aa 482-496), m/z = 542.906, +3, 1P (pS484)
Mass error: 2.0 ppm, Mascot Ion score: 93.0
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Nerbonne_029_2506_263_10_ #6115.6 (TripleTOF 5600, high-resolution MS2)
LSSGTEDGGDDRLPK(pS)DSEDGPR (aa 482-504), m/z = 618.266, +4, 1P (pS497)
Mass error: 2.5 ppm, Mascot Ion score: 55.6
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Nerbonne_029_2506_011_05_ #992 (LTQ-Orbitrap XL, low-resolution MS2)
SD(pS)EDGPR (aa 497-504), m/z = 471.665, +2, 1P (pS499)
Mass error: 3.6 ppm, Mascot Ion score: 38.2
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Nerbonne_029_2506_291_10_ #8260 (LTQ-Orbitrap Elite, high-resolution MS2)
ALNQL(pS)LTHGLSR (aa 505-517), m/z = 745.380, +2, 1P (pS510)
Mass error: -0.55 ppm, Mascot Ion score: 69.7
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Nerbonne_029_2506_291_10_ #8262 (LTQ-Orbitrap Elite, high-resolution MS2)
ALNQL(pS)LTHGLSR (aa 505-517), m/z = 497.256, +3, 1P (pS510)
Mass error: 0.46 ppm, Mascot Ion score: 52.2
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Nerbonne_029_2506_263_10_ #8498.5 (TripleTOF 5600, high-resolution MS2)
497.260
ALNQLSLTHGL(pS)R (aa 505-517), m/z = 497.260, +3, 1P (pS516)
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Mass error: 7.5 ppm, Mascot Ion score: 52.7
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Nerbonne_029_2506_291_10_ #8806 (LTQ-Orbitrap Elite, high-resolution MS2)
SSRGSIFTFR (aa 524-533), m/z = 619.290, +2, 1P (pS524 and/or pS525)
Mass error: 0.10 ppm, Mascot Ion score: 27.1

555.295

SSR GSIFTFR

1000
955

100

MS1

90
Relative Abundance

y7

900

619.290

855
800
755
700

80
70
60
50

619.791

40
30
620.293

20

620.794

10
0

655

619.2

619.5

619.8

Relative Abundance

570.302

620.1
m/z

620.4

620.7

600
555

y1

500
455
400

175.119
129.102

y7

355
300

827.444

481.814

255

531.777

200
155
100

183.146

266.120 305.157

200

300

620.395
645.404

444.532

400

y5

717.364 760.415

498.834

500

600

700
m/z

Supplementary Figures 1. Burel et al.

y6
770.418

683.383

423.231
358.208

55
00

y3

159.089

818.420
800.403

800

907.483
1127.852

895.844

900

1000

1100

1200

Nerbonne_029_2506_263_10_ #6370.2 (TripleTOF 5600, high-resolution MS2)
DQG(pS)EADFADDENSTAGESESHR (aa 536-558), m/z = 845.312, +3, 1P (pS539)
Mass error: -0.88 ppm, Mascot Ion score: 141.5
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Nerbonne_029_2506_263_10_ #7326.3 (TripleTOF 5600, high-resolution MS2)
RP(pS)TQGQPGFGTSAPGHVLNGK (aa 569-590), m/z = 569.029, +4, 1P (pS571)
Mass error: 5.4 ppm, Mascot Ion score: 74.5
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Nerbonne_029_2506_011_01_ #9337 (LTQ-Orbitrap XL, low-resolution MS2)
AL(pS)AVSVLTSALEELEESHRK (aa 662-682), m/z = 783.731, +3, 1P (pS664)
Mass error: 3.9 ppm, Mascot Ion score: 50.1
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Nerbonne_029_2506_263_10_ #8081.5 (TripleTOF 5600, high-resolution MS2)
KPAALATHSQLPSC(+57)IAAPR(pS)PPPPEVEK (aa 993-1020), m/z = 758.148, +4, 1P (pS1012)
Mass error: 13 ppm, Mascot Ion score: 100.3

b18

KPAALATHSQLPSC(+57)IAA P R(pS) PPPPEVEK
y8

y11

758.648

450
400

MS1

758.399

350
Intensity

300
250
200
150
100
50

758.148
758.899
759.148
759.402

759.651 759.909
0
758.0 758.3 758.6 758.9 759.2 759.5 759.8 760.1
m/z

b172+
b182+

Supplementary Figures 1. Burel et al.

Nerbonne_029_2506_263_10_from 208.625 to 208.683 min (TripleTOF 5600, high-resolution MS2)
AANP(pS)KISYEPITTTLR (aa 1884-1900), m/z = 647.994, +3, 1P (pS1888)
Mass error: 0.3 ppm
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Nerbonne_029_2506_263_10_ #6296.8 (TripleTOF 5600, high-resolution MS2)
Q(-17)QAGSSGLSDEDAPER (aa 1933-1948), m/z = 855.334, +2, 1P (pS1937 and/or pS1938)
Mass error: -3.8 ppm, Mascot Ion score: 106.9
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Nerbonne_029_2506_263_10_ from 112.322 to 112.453 (TripleTOF 5600, high-resolution MS2)
QAG(pS)(pS)GLSDEDAPER (aa 1934-1948), m/z = 560.211, +3, 2P (pS1937 and pS1938)
Mass error: -11.4 ppm
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Nerbonne_029_2506_263_10_ #6165.3 (TripleTOF 5600, high-resolution MS2)
AT(pS)DNLPVR (aa 1987-1995), m/z = 526.742, +2, 1P (pS1989)
Mass error: 0.41 ppm, Mascot Ion score: 39.2
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